AbsTrACT
Objectives to investigate the association of the charlsoncomorbidity index (cci) with clinical outcomes after transcatheter aortic valve implantation (taVi). background Patients undergoing taVi have high comorbid burden; however, there is limited evidence of its impact on clinical outcomes. Methods Data from 1887 patients from the UK, canada, spain, switzerland and italy were collected between 2007 and 2016. the association of cci with 30-day mortality, Valve academic research consortium-2 (Varc-2) composite early safety, long-term survival and length of stay (los) was calculated using logistic regression and cox proportional hazard models, as a whole cohort and at a country level, through a two-stage individual participant data (iPD) random effect metaanalysis. results Most (60%) of patients had a cci ≥3. a weak correlation was found between the total cci and four different preoperative risks scores (ρ=0.16 to 0. 29) , and approximately 50% of patients classed as low risk from four risk prediction models still presented with a cci ≥3. Per-unit increases in total cci were not associated with increased odds of 30-day mortality (Or 1.09, 95% ci 0.96 to 1.24) or Varc-2 early safety (Or 1.04, 95% ci 0.96 to 1.14) but were associated with increased hazard of long-term mortality (hr 1.10, 95% ci 1.05 to 1.16). the two-stage iPD meta-analysis indicated that cci was not associated with los (hr 0.97, 95% ci 0.93 to 1.02). Conclusion in this multicentre international study, patients undergoing taVi had significant comorbid burden. We found a weak correlation between the cci and well-established preoperative risks scores. the cci had a moderate association with long-term mortality up to 5 years post-taVi.
InTrOduCTIOn
In patients with severe symptomatic aortic stenosis (AS) who are considered at high or intermediate operative risk, transcatheter aortic valve implantation (TAVI) has become a standard alternative to surgical aortic valve replacement (SAVR). 1 Validated scoring systems permit the estimation of operative risk according to patients' clinical profile and the type of intervention. [2] [3] [4] The
Charlson Comorbidity Index (CCI) is a global measure of comorbidity burden 5 6 that was developed and validated for estimating prognosis and adverse clinical outcomes in a broad spectrum of patients, including those undergoing coronary and valvular heart interventions. [7] [8] [9] [10] While the Heart Team considers the presence of multiple comorbid conditions of patients during their decision-making processes for TAVI eligibility, the association of comorbid burden with clinical outcomes is mainly limited to single centre studies. 7 9 Therefore, the aim of this multicentre international study was to report the distribution of comorbidity burden in patients undergoing TAVI and the association with short-term and long-term clinical outcomes, as well as length of stay (LoS) after TAVI.
MeThOds Participants
This analysis included prospective data collected between 2007 and 2016 on all TAVI procedures undertaken across four UK-TAVI centres (Queen Elizabeth Hospital (Birmingham), University Hospital of North Staffordshire (Stoke-on-Trent), University Hospital of Wales (Cardiff) and New Cross Hospital (Wolverhampton)) and four non-UK TAVI centres (University Hospital, London Health Sciences Centre (Ontario, Canada), Cardiovascular Institute, Hospital Clínico San Carlos (Madrid, Spain), Heart Center Lucerne (Lucerne, Switzerland) and University Hospital of Udine (Udine, Italy)). The UK-derived data were extracted from those submitted to the UK TAVI registry, 11 12 while the non-UK data were derived from each individual centre's databases. The variables recorded across all databases included patient baseline demographics, preprocedural risk factors, periprocedural/postprocedural information and outcomes occurring before index hospital discharge. For UK patients, all-cause long-term mortality information was available through linkage with the Office for National Statistics, and for non-UK patients, this information was collected either by last available on-site clinical visit or by telephone contacts. The research ethics boards at the participating sites approved the datasets for the study.
Comorbidity burden measurement
The CCI was used as a measure of comorbid burden 13 and was retrospectively calculated for each patient based on baseline clinical profile across all contributing centres. The 19 components of CCI are: previous myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, mild or severe liver disease, diabetes with or without end-organ damage, moderate to severe chronic kidney disease, haemiplegia, leukaemia, lymphoma, any tumour with or without metastases and AIDS status. Each of the components has an associated weighting, which is summed across the 19 conditions to define the total CCI score; thus, higher values indicate increasing comorbid burden.
statistical analysis
Continuous data were described using the mean and range of values, with group comparisons made using analysis of variance. Likewise, categorical data were presented as raw number of events and corresponding percentages, with comparisons made using the χ 2 test. The primary outcomes in this analysis were 30-day mortality and long-term survival. Secondary outcomes were LoS (defined as the number of days between admission and discharge) and the Valve Academic Research Consortium-2 (VARC-2) composite early safety endpoint (defined as any of the following occurring within 30 days: mortality, stroke, life-threatening bleed, acute kidney injury, coronary artery obstruction, major vascular complication and valve-related dysfunction). 14 The impact of comorbidity on each outcome was examined with total CCI modelled as both a continuous variable (ie, the effect of per-unit increases in total CCI) and across strata of CCI=0, CCI=1, CCI=2, CCI=3, CCI=4, CCI=5 and CCI=6+ (to examine non-linear relationships between total CCI and the outcomes).
Patients with missing information that precluded CCI calculation were excluded from the analysis. Similarly, patients with missing endpoint data were removed from the analysis of that specific endpoint. Missing covariate information was imputed using multiple imputation by chained equations, where we generated 10 imputed datasets. 15 The imputation models for each covariate included the majority of other baseline covariates, total CCI, each of the considered endpoints and a random effect at the country level. 16 17 All subsequent analyses were performed within each imputed dataset, with parameters of interest pooled across imputations using Rubin's rules. 15 Baseline patient risk was summarised with the Logistic Euro-SCORE (LES), 3 the EuroSCORE-II (ESII), 18 Society of Thoracic Surgeons (STS) Predicted Risk of Mortality 4 and the TAVI-specific FRANCE-2 19 prediction models. These models were calculated in the multiple imputed data and were averaged across imputations. Spearman's rank correlation coefficients were calculated to determine the strength of the correlation between total CCI and each risk model.
Associations between CCI and the binary endpoints (30-day mortality/VARC-2 composite early safety) were examined with logistic regression, with unadjusted, age and sex adjusted and multivariable adjusted ORs reported. Similarly, the effect of CCI on long-term survival and LOS was examined non-parametrically using Kaplan-Meier plots, with multivariable adjusted HRs estimated with Cox proportional hazards models. Long-term survival was modelled up to 5-year postprocedural follow-up.
Each of the multivariable adjustments included all baseline/ procedural variables that were (A) recorded across all the datasets and (B) not components of the CCI, or on the causal pathway between CCI and outcome. Specifically, the following variables were included in the multivariable adjustment: age, sex, smoking status, atrial fibrillation, height, weight, New York Heart Association (NYHA) Functional Classification, coronary artery disease, pulmonary hypertension (>60 mm Hg), aortic valve area, left ventricular ejection fraction (LVEF), non-elective procedure indication and non-transfemoral access route indication.
When analysing the data as a whole cohort, we included a random effect (ie, random intercept) at a country level within each of the analysis models, thereby aiming to respect the clustering of the data collection. Similarly, we also performed a two-stage individual participant data (IPD) meta-analysis at a country level. Here, data from each country were analysed individually, and the results from which were then pooled using a random effects model across countries. 20 21 The multiple imputation was incorporated into this process by first applying Rubin's rules at the country level prior to pooling the country-specific estimates using meta-analytical techniques. 22 Sensitivity analyses for the two-stage approach were undertaken analysing all data simultaneously, including an interaction term in the models between CCI and country, and between age groups and total CCI.
All analyses were performed using R V.3.4.2. 23 Graphical plots were made using the 'ggplot2' package, 24 the 'mice' package was used for the multiple imputation 25 and the meta-analysis was performed with the 'metafor' package.
resulTs
Between August 2007 and September 2016, data for n=1887 patients were available, comprising 791, 308, 181, 375 and 232 patients from the UK, Canada, Italy, Spain and Switzerland, respectively. Patient baseline characteristics as a whole cohort and across strata of CCI are given in table 1; similarly, online supplementary table 1 presents baseline characteristics by country. The mean age of patients was 81.6 years with 51.4% male. Most procedures were undertaken electively and via transfemoral access (83%). The proportion of patients with atrial fibrillation/flutter (p=0.045), previous balloon aortic valvuloplasty (p<0.001), previous percutaneous coronary intervention (p<0.001), NYHA class III/IV (p=0.003), coronary artery disease (p<0.001), LVEF <50% (p<0.001) and undergoing non-elective procedures (p=0.007) varied significantly across strata of total CCI (table 1) .
The distribution of total CCI for the whole cohort and by country is given in figure 1A . The median total CCI was 3 (IQR: 2-4), with a minimum of 0 and maximum of 11. Across all countries, the majority of patients had a total CCI of 3 or more, with the proportion of patients with CCI ≥3 ranging from 56% (UK) to 72% (Switzerland) (figure 1B). The most common cardiovascular comorbidities were previous myocardial infarction (24%) and congestive heart failure (59%), while the most common non-cardiovascular comorbidities were chronic kidney disease (50%) and chronic obstructive pulmonary disease (21%) (online supplementary figure 1).
CCI And esTAblIshed rIsk MOdels
We calculated the LES, ESII, STS and the FRANCE-2 prediction models for all patients. Unsurprisingly, the proportion of patients with higher CCI scores increased across quantiles of the predicted risks from each model (figure 2). Nevertheless, even within the lowest predicted risk quantile of each risk A total of 1555 patients had data on long-term survival, totalling 3663 person-years of follow-up. The overall 6-month, 1-year and 2-year survival estimates were 91.0%, 87.9% and 79.8%, respectively. Across CCI strata, 1-year survival rates were 95.1%, 89.3%, 90.6%, 88.1%, 82.5%, 87.1% and 85.0% for CCI=0, CCI=1, CCI=2, CCI=3, CCI=4, CCI=5 and CCI=6+, respectively. A univariable Cox proportional hazards model indicated that the hazard of mortality was significantly higher for unit increases in total CCI (HR 1.11, 95% CI 1.06 to 1.16; table 2). The hazards of mortality remained significantly higher for unit increases in total CCI after adjusting for age and sex (HR 1.11, 95% CI 1.06 to 1.17), and after multivariable adjustment (HR 1.10, 95% CI 1.05 to 1.16). Similarly, long-term survival differed significantly across strata of CCI=2, CCI=3, CCI=4, CCI=5 and CCI=6+ as compared with those with a CCI=0 (table 3) . The two-stage IPD meta-analysis on hazards for long-term mortality across each participating country resulted in a pooled HR (multivariable adjusted) of 1.13 (95% CI 0.98 to 1.30) per unit increases in total CCI (figure 3B). For clarity, figure 4A depicts the Kaplan-Meier plot across four CCI strata, while figure 4B shows that across all seven strata used in the main analysis.
Valvular heart disease

length of stay
Across the whole cohort, 1820 (96%) patients had information on their LoS, with a median LoS of 7 days (IQR 5-13 days). Unit increases in total CCI were not associated with longer LoS after multivariable adjustment (HR: 1.00, 95% CI 0.97 to 1.02; table 2). Similar findings were observed within the two-stage IPD meta-analysis with a combined meta-analysis HR of 0.97 (95% CI 0.93 to 1.02; figure 3C ). Analyses for non-linear relationships between CCI and LoS indicated that the multivariable adjusted HRs for a shorter LoS were 1.30 (95% CI 1.02 to 1.66), 1.40 (95% CI 1.10 to 1.77) and 1.36 (95% CI 1.07 to 1.73) for patients with CCI=1, CCI=2 and CCI=3, respectively, but were not significantly different for CCI >3 compared with CCI=0 (table 3) .
VArC-2 composite early safety
A total of 745 patients were removed due to missing data on the VARC-2 composite early safety outcome (ie, patients who were missing components of the composite outcome). Hence, 1142 (60.5%) patients had information on the VARC-2 composite early safety outcome, of which the event rate was 18.6%. After multivariable adjustment, the odds of the VARC-2 composite early safety outcome were not significantly different with per-unit increases in total CCI (table 2) or across strata of total CCI (table 3) .
sensitivity analyses
Sensitivity analysis for the two-stage approach was undertaken analysing all data simultaneously, including an interaction term in the models between CCI and country. The results are quantitatively similar to those from the two-stage approach (online supplementary table 2). Further sensitivity analysis between age groups (<65, 65-75, 75-85 and >85 years) and total CCI Valvular heart disease Patients with CCI=0 were used as the reference group. Each model includes a random intercept at the country level. *The multivariable model adjusted for the following variables: age, sex, smoking status, atrial fibrillation/flutter, height, weight, New York Heart Association class, coronary artery disease, pulmonary hypertension, aortic valve area, left ventricular ejection fraction, non-elective procedure indication and non-transfemoral access route. VARC-2, Valve Academic Research Consortium-2.
(as a continuous variable) show that the HRs/ORs are similar across age groups and the age group-CCI interaction terms were non-significant, suggesting that the relation of comorbidity to outcome is similar across age groups (online supplementary table  3) .
dIsCussIOn
In this multicentre international study, the majority of patients who underwent TAVI presented with significant comorbid burden, with most having a CCI of ≥3. We found a weak correlation between the CCI and well-established preoperative risks scores and even patients classed as low preoperative risk presented with a CCI ≥3 in approximately 50% of the cases.
Patients with a CCI between 1 and 3 had shorter LoS than those with CCI=0, but higher values of CCI were not associated with differences in LoS. The CCI was associated with increased hazard of mortality up to 5 years post-TAVI. The CCI is a validated tool to assess comorbidity burden and has been shown to be a predictor of outcome in patients with AS. 7 9 However, we may have to consider that TAVI candidates with a CCI=0 are unlikely to be truly 'without comorbidity' and may merely have prevalent comorbid conditions not captured by the CCI. Explicitly, it is likely that patients undergoing TAVI presenting a CCI=0 are more comorbid as compared with those in the general population given that they are considered not suitable for SAVR. Therefore, the cohort of patients with a CCI=0 are likely to represent a high-risk cohort by virtue of other comorbid conditions not captured by CCI.
Comorbidity burden and mortality
Our results indicate that comorbidity burden assessed by the CCI was not associated with significantly higher odds of 30-day mortality, yet it was in the long term. These results are in line with previous reports. 7 9 27 A potential explanation is that procedural-related variables have a greater impact on in-hospital and 30-day mortality, 27 28 but (other than stroke within 30 days) procedural variables do not impact long-term survival following TAVI. 28 These findings support the theory that comorbid conditions have a greater impact on long-term mortality than the index TAVI procedure. Indeed, it is known that in intermediate to high-risk patients, the majority die from non-cardiac conditions. 9 27 The current analysis suggests that CCI score moderately correlated with survival up to 5-year postprocedure across multiple countries/centres, each with different practices and valve types. Therefore, the use of CCI may potentially serve as a measure to estimate long-term mortality as compared with standard risk assessment.
Comorbidity burden and los
The results from this analysis indicate that CCI was generally not associated with LoS, although there was evidence that CCI scores between 1 and 3 had shorter LoS; however, as discussed above, this is likely due to TAVI candidates who are recorded as CCI=0 not being truly 'without comorbidity'. Hence, one needs to interpret these findings with caution given that LoS is driven by several clinical but also non-clinical factors (eg, home circumstances and country or centre-specific practices for discharge). Moreover, centres that predominantly use self-expanding TAVI devices may delay discharge due to perceived need for later permanent pacemaker implantation. Additionally, the time period of the analysis (2007-2016) includes temporal changes to TAVI practice, such as the introduction of conscious sedation and new device technology, which could not be adjusted for in this analysis; future analyses on contemporary cohorts of TAVI patients could investigate this further.
CCI and preoperative risk assessment
The poor performance of the STS score and the LES/ESII are due to the fact that they were derived for predicting surgical populations with different clinical characteristics from those of TAVI cohorts. 29 Thus, precluding accurate model calibrations to perform in TAVI patients that were excluded from SAVR by virtue of certain comorbidities, such as porcelain aorta, chest radiation/hostile chest, cancer, immunodeficiency, liver disease/ cirrhosis and frailty that, among others, are not computed into the STS score and LES/ESII risk models. Moreover, it might also artificially exaggerate the positive results obtained with either surgical or transcatheter procedures. 30 However, this would also apply for the CCI and the rationale for assessing its value in TAVI populations. Our results show a weak correlation between the CCI and STS score, LES, ESII and FRANCE-2 scores. Importantly, even those patients classed as low preoperative risk were still relatively comorbid as defined by a CCI≥3 in approximately 50% of the patients. These results suggest that the risk models do not capture several aspects of preoperative risk but, however, some variables included in the CCI are also considered for the calculation of above mentioned risk scores.
limitations
Several limitations need to be considered. First, although our results were obtained from prospectively gathered datasets, the retrospective nature of the analysis are exposed to potential (unmeasured) confounders. Therefore, we cannot interpret the results as causal, but rather they represent associations between CCI and the investigated outcomes. Second, in most centres, we only had data on CCI as a quantification of comorbid burden. Although this is a widely used and validated measure of estimating prognosis and adverse clinical outcomes, the findings may differ if other comorbidity scales were used. Third, a relatively large number of patients were removed from the analyses due to missing endpoint data, which could affect the results. Fourth, the 9-year data collection period includes patients treated back in 2007, where the majority of patients may have been inoperable or high risk with relevant comorbidities precluding SAVR. However, the inoperable state of these patients may have not been reflected in the CCI and associated with higher CCI levels. Moreover, several iterations of transcatheter valve technology and evolutions of procedural practice, which potentially make those data derived from earlier years of less applicability to contemporary practice. Finally, as discussed above, TAVI patients with a CCI=0 are unlikely to be representative of those in the general population with CCI=0, which could dilute potential associations. Future studies may help determine the associations between comorbidity burden and other important outcomes after TAVI, such as hospital readmission and quality of life.
COnClusIOn
In this multicentre international study, the majority of patients who underwent TAVI presented with three or more comorbid conditions as assessed by the CCI. We found a weak correlation between the CCI and standard preoperative risks scores. Notably, even those patients classed as low preoperative risk presented with a CCI≥3 in about 50% of the patients. The CCI was associated with increased hazard of mortality up to 5 years post-TAVI, suggesting that CCI is a potentially useful measure to assess long-term outcomes compared with standard risks assessment. the heart and lung centre, the royal Wolverhampton hospitals nhs trust, Wolverhampton, UK 10 Department of cardiology, University hospital of Wales, cardiff, UK Acknowledgements the authors would like to thank all members of heart teams of each participating centre.
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